Genéricas

GENinCode Plc are pleased to announce the publication of its Thrombo inCode® prospective case-control study performed at the Karolinska Institute, Sweden. The positive clinical results strengthen [...]

GENinCode the predictive genetics and cardiovascular disease company focused on the prevention of cardiovascular disease is thrilled to announce the completion of its IPO and subsequent listing [...]

GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces its partnership with EVERSANA Life Sciences LLC [...]

GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today a collaboration with Royal Brompton and [...]

GENinCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the appointment of Bill Rhodes [...]

GENinCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease announces today the appointment of Paul Foulger [...]

Dr Luis Rincon’s performed his recent study into cardiovascular disease genetic risk scoring and its use to help predict secondary or recurrent cardiac events, after myocardial infarction, [...]

The 34th National Congress of the Italian Society for the Study of Atherosclerosis (SISA) took place virtually on the 22nd of November. The Congress addressed several topics of interest in the [...]

The much-anticipated UK Genomic Health Strategy has now been published! ‘The strategy sets out an ambitious and compelling vision for how to create the most advanced genomic healthcare [...]

On the 8th October our Scientific & Medical Manager, Dr Marta Carrera, attended as a key speaker at the Spanish Familial Hypercholesterolemia (FH) Foundation Conference presenting the [...]

World Heart Day (29th September) is an international, educational, campaign day for cardiovascular disease. Not just this day, but every day, lifestyle and preventative measures to reduce the [...]

GEN inCode UK Limited the privately owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease announces today the completion of a £3.0m [...]

As part of our ongoing plan to combat the SARS-CoV-2 virus (Covid-19) and in response to the needs of our customers and collaborating health care partners, GEN inCode are now offering Covid-19 [...]

Due to the unprecedented circumstances relating to Severe Acute Respiratory Syndrome Coronavirus-2  (SARS-CoV-2 or COVID-19), some of the services of GEN inCode may be modified in accordance with [...]

London and Barcelona, February 13, 2019 The International Journal of Sciences published the results of the study “Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk [...]

On September 12, 2018 GEN inCode acquired the personalized medicine service of the products Cardio inCode®, Lipid inCode®, SudD inCode® and Thrombo inCode® and the assets and know-how of the [...]